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Augmentation Index in Marfan-Like Syndromes in 32 individuals, and we analyzed the relationship between increased arterial stiffness or pulse wave reflection, and aortic disease evolution.
Methods
Study characteristics and population. We enrolled all patients with Marfan-like features, exclusion of MFS as defined by the Ghent nosology, 12 and no previous cardiovascular surgery or intervention. 8 All patients were >17 years, and all patients presented to our center within a period of 2-1/2 years. 8 We excluded patients with pacemakers, patients with clinical or serologic signs of inflammation, persons not in sinus rhythm or with heart rates >100 beats/min as obtained on an initial 12-lead standard electrocardiogram, individuals with systolic blood pressures >140 mm Hg or with diastolic blood pressures >90 mm Hg after 15-min rest on standard sphygmomanometer, patients with left ventricular systolic ejection fraction <60% or with heart valves with any regurgitation or stenosis more than first degree on standard transthoracic echocardiography obtained on the day of APT.
We considered 288 consecutive outpatients for inclusion in our study. Of these 288 persons, 86 persons had previously undergone cardiovascular surgery or intervention, 75 persons fulfilled criteria of MFS, 37 persons failed to conform to the inclusion criteria, 6 persons did not complete our diagnostic program, 3 persons exhibited inadequate APT measurements, and 3 persons refused to participate. The remaining 78 individuals constituted our study group that comprised 46 men and 32 women at a mean age of 34 ± 13 years (range 18-72 years; Table 1 ).
All patients were assessed for all clinical criteria of the Ghent nosology. 12 We established the final diagnosis in each patient as described previously. 8 Final diagnoses comprised LDS, 9 MASS phenotype, 12, 15 mitral valve prolapse syndrome, 12, 16 familial TAAD, 10 vascular type of EDS, 11 nonsyndromic BAV, 7 familial ectopia lentis, 12 and familial Marfan-like habitus ( Table 2) . 13 In the other 48 individuals, current diagnostic criteria were not applicable to establish a final diagnosis. In these individuals, we report the presenting Marfan-like feature, according to our standardized catalog ( Table 3) . 8 We followed patients by phone interview and performed echocardiography after APT. The Hamburg Research Ethics Committee approved our study, which was in accordance with the principles of the Declaration of Helsinki. 2 All subjects gave written informed consent for their participation in the study. 2 Demographic and clinical characteristics. We assessed all epidemiological and clinical characteristics prior to APT using our standardized criteria. 2, 8 In brief, we assessed age at the time of APT, body weight, body height, body mass index, 2 and body surface area (BSA). 17 We measured maximum aortic diameters at the level of the aortic sinuses and at the level of the ascending aorta on transthoracic echocardiography. 18 We calculated 95th percentiles of normal diameters (cm) for each man at the aortic sinuses = 2.250 + 0.023 × age − 0.00014 × age 2 + 0.486 × BSA, and at the level of the ascending aorta = 1.691 + 0.028 × age − 0.00009 × age 2 + 0.505 × BSA; and for each woman at the aortic sinuses = 2.145 + 0.021 × age − 0.00014 × age 2 + 0.448 × BSA, and at the level of the ascending aorta = 1.614 + 0.028 × age − 0.00012 × age 2 + 0.525 × BSA, 19 where BSA (m 2 ) was calculated with the DuBois formula. 17 Then we subtracted these calculated normal values of each aortic diameter at the 95th percentile (cm) from the aortic diameters as obtained in each individual (Δ95th percentile; Tables 2 and 3). We considered aortic medication with isolated or combined chronic intake of β-blockers (ID 15, 17, 18, 25, 28, 70, 74, 75 , and 78; Tables 2 and 3), ACE inhibitors (ID 18), AT1 blockers (ID 74), or calcium antagonists (ID 7, 24, 42, 49, and 78) according to our medication protocols. 2 We considered active smoking with inhalative intake of nicotine within ≤7 days of the study, and we assessed fasting blood glucose levels and fasting lipid levels ≤24 h, and glomerular filtration rates as estimated according to the Modification of Diet in Renal Disease study 20 prior to APT ( Table 1) .
Hemodynamic characteristics. We performed APT using our previously described protocol, 2 which was in accordance with international guidelines. 21 We continued all medications during APT. All investigators were blinded to clinical data, diagnoses, or therapy of our patients. We averaged values from three consecutive APT measurements, with acceptance as valid only with standard deviation of beat-tobeat data <10% of its mean and complying with the internal SphygmoCor quality control criteria. 2 We obtained radial artery waveforms from the wrist of the dominant arm using a high-fidelity micromanometer (SPC-301; Millar Instruments, Houston, TX). 2 A validated transfer function (SphygmoCor; AtCor Medical, Sydney, Australia) generated the corresponding central waveforms, and the integral SphygmoCor software determined central blood pressures, AIx, the time to the peak/shoulder of the first (T1) and second pressure wave components (T2) during systole, the time to return of the reflected pressure wave (Tr), ejection duration, CPP, and heart rates. 2 We used the AIx adjusted to a heart rate of 75 beats/min (AIx@HR75). We obtained the mean arterial pressure, and the subendocardial viability ratio (or Buckberg's ratio) from integrals of the central waveform. The blood pressure level was measured oscillometrically at the upper arm (Omron HEM 750; Omron Healthcare, Kyoto, Japan). To measure the carotid-femoral pulse wave velocity, we sequentially recorded electrocardiogram-gated carotid and femoral artery waveforms; the traveled distance of the pulse wave was assessed as the distance from the suprasternal notch to the femoral artery with subtraction of the distance from the carotid to the suprasternal notch (Tables 1 and 4) . 2 Genetic testing. We performed molecular genetic analysis in 36 individuals. We extracted DNA from EDTA-blood using standard procedures. The entire coding sequence and flanking intronic sequences of the FBN1, TGFBR1, and TGFBR2 genes were amplified by PCR and sequenced as described previously. 22, 23 original contributions
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Follow-up. We performed a phone interview in all study patients 20 ± 18 months after APT using a structured questionnaire to document aortic events including aortic dissection or aortic intervention, and current health status including major adverse cardiovascular events. 2, 24 We invited all patients for follow-up echocardiography, which we performed in only 32 individuals including 3 individuals who developed aortic dissection (ID 18) or who required elective aortic operation (ID 20 and 23). We documented an aortic event with aortic dissection, or aortic rupture, or aortic surgery or aortic intervention occurring after APT, and we compared standardized echocardiographic measurements at the level of the aortic sinuses and at the ascending aorta at the time of APT and during follow-up for progression of aortic diameters. No patient died or developed other major adverse cardiovascular events or required other major surgery or intervention. (ID 18, 20, 21, 22, 24, 27, 28, and 30) .
In the remaining 48 individuals, we found skeletal abnormalities in 22 persons (30%), a family history in 21 persons (27%), unexplained spontaneous pneumothorax in 2 persons (3%), unexplained dissections of the carotid arteries in 2 persons (3%), or tissue weakness and joint hypermobility in 1 person (1%). During follow-up, we observed progression of aortic diameters ≥5 mm in 7 individuals, but no aortic dissection or need for aortic surgery or intervention (ID 60, 64, 67, 71, 73, 76, and 77; Table 3 ). All 7 patients with progression of aortic diameters exhibited AIx@HR75 >11%, including 6 individuals with aortic diameters ≤95th percentile (ID 60, 64, 67, 71, 73, and 76). We did not observe progression of aortic diameters or aortic events after APT in individuals with AIx@HR75 <11% (Tables 2 and 3) .
Regression analysis showed that all but two individuals with aortic events had AIx@HR75 values above the age-dependent expected mean of the AIx@HR75 (Figure 1) . Similarly, CPPs tended to be increased in persons with aortic disease progression (Figure 1) . Conversely, only four individuals with aortic Δ95th, difference of diameters obtained in study patients at baseline minus diameter (cm) at 95th percentile; AIx@HR75, augmentation index at heart rate 75; APT, applanation tonometry; CPP, central pulse pressure; Dia, diameter (cm); Diss carot, presence of otherwise unexplained spontaneous dissection of carotid arteries; Fam hist, a family history with a parent, child, or sib independently meeting diagnostic criteria of MFS, or having aortic dissection or aneurysm, or having suffered sudden unexplained death at an age of ≤40 years; Hypermob, marked signs of tissue weakness or joint hypermobility; Pneu, presence of otherwise unexplained pneumothorax; Skel, skeletal features such as unusual body height, severe scoliosis, or sternum deformities alone or in combination; TTE, transthoracic echocardiography.
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Augmentation Index in Marfan-Like Syndromes events exhibited aortic diameters >95th percentile of normal at baseline (Figure 2) . Unlike central systolic blood pressure, aortic T2, time to return of reflected pulse wave, CPP, and pulse wave velocities were similar in individuals with echocardiography performed for analysis of aortic disease progression ( Table 4) . We performed this observational study to explore whether AIx@HR75 and CPPs related to the evolution of aortic disease in adults with Marfan-like features but no MFS. Indeed, we found that patients with signs of evolving aortic disease exhibited AIx@HR75 ≥11% at baseline. We found increased AIx@ HR75 and increased CPPs in patients with progression of aortic disease irrespective of their underlying syndrome or their aortic diameters at baseline. Larger studies with comprehensive clinical and echocardiographic follow-up over long time intervals are now needed to establish APT for prediction of aortic disease progression in Marfan-like syndromes.
hemodynamic characteristics
Classic pathogenetic concepts consider aortic aneurysm to result either from arterial hypertension in older patients or in younger patients from inherited weakness of the aortic tissue. [25] [26] [27] Our findings suggest that despite normal peripheral blood pressures, CPP, and AIx@HR75 play a role in the progression of aortic disease in young individuals with Marfan-like syndromes such as EDS 11 and LDS. 28 To tailor optimal medical therapy for prevention of aortic aneurysm, it may thus be useful to assess drug effects on CPP and AIx@ HR75. In contrast to AIx@HR75 and CPP that increase already at younger age, 1 pulse wave velocity is expected to increase in healthy individuals >50 years of age. 29 clinical and molecular characteristics
Our findings underline that clinical characteristics may not be useful to predict aortic events in Marfan-like syndromes. Most notably, aortic diameters were normal at baseline in most persons with subsequent progression of aortic diameters. Moreover, we observed progression of aortic disease in various Marfan-like syndromes and even in persons without any defined syndrome. In contrast, identification of gene mutations provided important information to stratify the individual aortic risk. We identified five individuals with progression of aortic disease who exhibited a mutation in the TGFBR1 gene (ID 30), the TGFBR2 gene (ID 17), or in the FBN1 gene (ID 28, 65, and 77). Both patients with a FBN1 gene mutation did not satisfy current criteria of MFS 12 despite an increased aortic risk. These findings might justify diagnosing MFS (ID 28) or TAAD (ID 65 and 77) in these patients despite lack of formal criteria. Conversely, we excluded a mutation in the genes TGFBR1/2 and FBN1 in six persons with increased AIx@HR75 and progression of aortic disease. It is possible that mutations in other genes than TGFBR1/2 and FBN1 are responsible for aortic disease in these patients. 14 Patients with mild variants of connective tissue syndromes such as Marfan-like habitus and ectopia lentis 14 exhibited low AIx@HR75 without evolution of aortic disease. However, we observed increased AIx@HR75 with progression of aortic diameters in seven individuals without defined syndromes and normal aortic diameters, which emphasizes the importance of APT to assess aortic tissue weakness in apparently normal individuals. Similarly, MASS phenotype is a mild variant of classical MFS with low aortic risk. 15 However, there is almost no data to document stability of aortic diameters. We observed normal aortic diameters with low AIx@HR75 in four MASS patients, whereas one person with MASS phenotype (ID 28) had increased AIx@HR75 and developed 5 mm progression of aortic diameters. We performed FBN1 gene analysis and found a mutation, which suggested nonclassical MFS rather than MASS phenotype. 15 Our patient with mitral valve prolapse syndrome did not exhibit increased CPP or AIx@HR75, which supports absence of aortic disease in this syndrome. 12 LDS is a severe disease, 9 which may yield aortic complications even in the neonatal 30 or prenatal period. 31 Our patients with LDS (ID 17 and 30) exhibited normal facial and skeletal features with normal aortic diameters and no arterial tortuosity. However, AIx@HR75 was increased, and both patients developed progression of aortic diameters. Similarly, the vascular type of EDS leads to early rupture of the aorta or of major aortic side-branches. 11, 32 Two of our three patients with vascular EDS (ID 22, 24, and 27) had normal aortic diameters at baseline with increased CPPs and AIx@HR75 values, and all patients developed progression of their aortic diameters. Heritable TAAD are caused by mutations in a broad spectrum of known and unknown genes, some of which involve aortic smooth muscle cell contractile protein expression, such as MYH11 and ACTA2 genes. 10 Only one (ID 26) of our patients with TAAD (ID 18, 20, and 26) had increased aortic diameters at baseline, but all individuals exhibited increased AIx@HR75 with progression of aortic disease including one individual with acute aortic dissection (ID 18). Increased aortic stiffness 33 and a risk for aortic complications 34 are also described in patients with a BAV, and current guidelines recommend low thresholds for elective aortic surgery. 35 We found AIx@HR75 ≥11% in five of six individuals (ID 15, 16, 21, 23, 25 , and 29) with a BAV including one patient who required replacement of the aortic root (ID 23) and one patient who developed progression of aortic root diameter despite normal aortic diameters at baseline (ID 21). Thus, APT may be useful to individualize risk stratification in patients with a BAV.
study limits
We showed recently that our patients are likely to represent the true prevalence in the normal Hamburg metropolitan area population, and thus, it is likely that the composition of our current study group is largely unbiased. 8 Moreover, we were able to obtain clinical follow-up information in all patients. In contrast to our Marfan patients with excellent compliance, 2, 36 only 41% of non-Marfan patients followed our invitation for follow-up echocardiography. However, the similar distribution of characteristics between individuals irrespective of follow-up echocardiography reduces the likelihood for major selection bias. Furthermore, our study is likely to underrate the true rate of aortic diameter progression, and the low frequency of aortic dissection and aortic surgery may be explained by comparatively short follow-up intervals. Aortic medication was unlikely to bias our results because medications were distributed similarly across patient groups (Tables 1 and 4) . Finally, the
